drugset
drugset / Trial / NCT03387475

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

NCT03387475 ↗

Phase 2 Completed 39 enrolled University Hospital, Grenoble Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

Patients with low-risk MDS verifying the eligibility criteria may be included in the study.

Timeline

Start
2018-02-20
Primary completion
2024-10-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 3.5 mg/kg —

Indications

myelodysplastic syndrome